news Time to renew the antibiotic arsenal 19 January 2016 | By Philippe Villain-Guillot, CEO, Nosopharm Philippe Villain-Guillot, CEO, Nosopharm, discusses antimicrobial resistance and the challenges facing antibacterial drug discovery and development...
news Nosopharm joins ENABLE to help combat antibiotic resistance 7 December 2015 | By Victoria White The €100m ENABLE project aims to identify at least three antibacterial lead molecules with promising antibacterial activity, two antibacterial clinical candidate molecules and to enter at least one compound into preclinical and Phase 1 clinical studies...
news Nosopharm hires four new international experts to its scientific advisory board 19 November 2014 | By Nosopharm These high-profile experts will help with the quick and safe launch of the preclinical development program for a new class of antibiotics...